Track topics on Twitter Track topics that are important to you
WATERTOWN, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies, today announced that Kei Kishimoto, Ph.D., CSO, will present at the Canaccord Genuity Growth Conference on Wednesday, August 10, 2016, at 9:30 am EDT at the InterContinental in Boston.
A live webcast will be available on the Investors & Media section of the Selecta website at www.selectabio.com. An archived replay will be available for approximately 90 days following the presentation.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company developing targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. Selecta's proprietary Synthetic Vaccine Particle (SVP) technology is a highly flexible nanoparticle platform, capable of incorporating a wide range of antigens and immunomodulators, allowing the SVP products to either induce antigen-specific tolerance or activate the immune system.
Selecta's focus is on developing and commercializing differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases by mitigating the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Tolerance-inducing SVP products also have potential applications in the treatment of allergies and autoimmune diseases.
Selecta is also developing SVP products that activate the immune system to prevent and treat cancer, infections and other diseases.
Selecta is based in Watertown, Massachusetts, USA.
For Selecta media: Kathryn Morris The Yates Network +1-845-635-9828 firstname.lastname@example.org For Selecta investors: Stephanie Ascher Stern Investor Relations, Inc. +1-212-362-1200 email@example.comNEXT ARTICLE
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...